Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Japanese Encephalitis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Japanese Encephalitis - Pipeline Review, H2 2015', provides an overview of the Japanese Encephalitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Japanese Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Japanese Encephalitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Japanese Encephalitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Japanese Encephalitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Japanese Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Japanese Encephalitis Overview 7 Therapeutics Development 8 Pipeline Products for Japanese Encephalitis - Overview 8 Pipeline Products for Japanese Encephalitis - Comparative Analysis 9 Japanese Encephalitis - Therapeutics under Development by Companies 10 Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes 11 Japanese Encephalitis - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Japanese Encephalitis - Products under Development by Companies 15 Japanese Encephalitis - Products under Investigation by Universities/Institutes 16 Japanese Encephalitis - Companies Involved in Therapeutics Development 17 Indian Immunologicals Limited 17 Panacea Biotec Limited 18 Sanofi 19 Vaxine Pty Ltd 20 Zydus Cadila Healthcare Limited 21 Japanese Encephalitis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 encephalitis vaccine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 FDX-000 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Japanese encephalitis vaccine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Japanese encephalitis vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Japanese encephalitis vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Japanese encephalitis vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Japanese encephalitis vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Japanese encephalitis vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Japanese encephalitis vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Japanese encephalitis vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Japanese encephalitis vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Japanese Encephalitis - Recent Pipeline Updates 42 Japanese Encephalitis - Dormant Projects 43 Japanese Encephalitis - Discontinued Products 44 Japanese Encephalitis - Product Development Milestones 45 Featured News & Press Releases 45 Dec 10, 2012: Sanofi Pasteur Launches Imojev First Single-dose Vaccine Against Japanese Encephalitis In Australia 45 Jun 29, 2007: Discontinuation of Japanese encephalitis vaccine 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for Japanese Encephalitis, H2 2015 8 Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Late Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Comparative Analysis by Unknown Stage Development, H2 2015 14 Products under Development by Companies, H2 2015 15 Products under Investigation by Universities/Institutes, H2 2015 16 Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2015 17 Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2015 18 Japanese Encephalitis - Pipeline by Sanofi, H2 2015 19 Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2015 20 Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 21 Assessment by Monotherapy Products, H2 2015 22 Number of Products by Stage and Target, H2 2015 23 Number of Products by Stage and Mechanism of Action, H2 2015 24 Number of Products by Stage and Route of Administration, H2 2015 26 Number of Products by Stage and Molecule Type, H2 2015 28 Japanese Encephalitis Therapeutics - Recent Pipeline Updates, H2 2015 42 Japanese Encephalitis - Dormant Projects, H2 2015 43 Japanese Encephalitis - Discontinued Products, H2 2015 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
